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Abstract
Introduction: Pressure ulcer-specific patient-reported outcome (PRO) instruments should be used to inform patient
care and provide a strong evidence base for interventions aimed at preventing pressure ulcers. The aim was to carry
out a comprehensive evaluation of the psychometric properties of a PRO instrument designed to assess symptoms
and functional outcomes in patients at high-risk of developing pressure ulcers, the PU-QOL-P instrument.
Methods: We modified the original PU-QOL instrument to be suitable for patients at high risk of pressure ulcer
development based on feedback from patients, specialist nurses and PRO methodologists. The modified PU-
QOL-P instrument was administered to a sub-set of patients participating in the PRESSURE 2 trial. Patients completed
PU-QOL-P and SF12 instruments at baseline, weeks 1 and 3, and 30 days post-treatment. We undertook psychometric
evaluation of the modified PU-QOL-P to test scale targeting, scaling assumptions, reliability, validity and responsiveness.
Results: The analysis sample consisted of 617 patients that completed both instruments at baseline. We found
that the PU-QOL-P instrument, consisting of nine PU-specific outcomes: three symptom and six function scales,
meets established criteria for reliability, construct validity, and responsiveness. Internal consistency reliability
was high with all scale Cronbach alpha > 0.795 (range 0.795–0.970). The factor analysis mostly supported the
six-function scale structure. Scaling assumptions were satisfied; all item-total correlations above 0.30. Convergent validity
was confirmed by significant correlations between hypothesized scales as expected. PU-QOL-P scales were responsive to
change: mean scale scores from baseline to 30 days post-treatment were statistically significant for all scales apart the
daily activities scale (effect sizes ranged from moderate to high). As expected, worse symptoms and functioning was
observed in patients who had a category 1 or 2 PU compared to patients who did not have a PU.
Conclusions: The PU-QOL-P provides a standardised method for assessing pressure ulcer-specific symptoms and
functional outcomes for quantifying the benefits of associated interventions from the patient’s perspective. It
can be used in research with adults at risk of pressure ulcer development in all UK healthcare settings.
Keywords: Pressure ulcer, Quality of life, Symptoms, Validation, Psychometrics
* Correspondence: claudia.rutherford@sydney.edu.au
1Quality of Life Office, School of Psychology University of Sydney, Level 6
North, Chris O’Brien Lifehouse C39Z, Camperdown, NSW 2006, Australia
Full list of author information is available at the end of the article
© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Rutherford et al. Health and Quality of Life Outcomes          (2018) 16:227 
https://doi.org/10.1186/s12955-018-1049-x
Background
Pressure ulcers (sometimes called bedsores, pressure
sores or pressure injuries) are a common chronic wound
defined as “localised injury to the skin and/or underlying
tissue usually over a bony prominence, as a result of
pressure, or pressure in combination with shear” [1].
With widespread prevalence and incidence in all health
settings [2], affecting approximately 1 in 7 hospital and 1
in 20 community patients [3, 4], pressure ulcer (PUs) are
a major burden to patients, carers, and healthcare
systems [5, 6].
PUs can cause distressing symptoms including pain [4,
7, 8], exudate and odour and compromise all areas of
patient functioning [5, 9]. Presence of symptoms and
functioning impairments can have a distal effect on
health-related quality of life (HRQOL) outcomes [10].
Intensive interventions for preventing and treating PUs
pose additional patient burden and further affect
HRQOL [9]. Additional impact on patients results from
increased care burden, prolonged rehabilitation, require-
ment for bed-rest, and hospitalisation [5, 10]. In this
clinical context, evaluating patient-reported outcomes
(PROs) such as symptoms, functioning, and HRQOL is
particularly important and relevant, and there is enor-
mous potential for PROs to be integral to treatment
assessment and recommendations for PUs.
The primary goal in managing patients at risk of PU
development is to minimise both the intensity and
duration of pressure exposure on vulnerable skin sites
(i.e. bony points of immobilised people such as hips,
heels and elbows), not adapted to sustained and/or
excessive loading, achieved by the provision of pressure
redistribution support surfaces (e.g. beds, mattresses,
mattress overlays and cushions) and patient reposi-
tioning [11, 12]. Support surfaces aim to prevent PUs by
relieving pressure and cushioning vulnerable parts of the
body, and distributing the surface pressure more evenly.
However, we know from studies [9, 13] and clinical ex-
perience that preventative interventions can directly
cause patients’ pain and discomfort, impact sleep quality
and limit physical function (e.g. mobility and movement)
that differs between interventions, and these proximal
effects can result in severe and persistent negative effects
on HRQOL. Therefore, assessment of symptoms and
impacts on HRQOL of different pressure redistribution
support surfaces should be considered when deciding
between management options for patients receiving
prevention interventions as well as during post-prevention
and treatment surveillance to enable better detection and
management of symptoms that impact patients’ HRQOL.
This in turn will improve psychological outcomes,
HRQOL, and the quality of patient care.
Our previous work has identified PROs important to
people with PUs [5, 9, 10], established the need for
patient-reported measures of outcomes specific to PUs
[14], and developed and evaluated a PRO instrument to
assess PU-specific symptoms and functioning impacts
(the PU-QOL instrument, accessed at: http://medhealth.
leeds.ac.uk/puqol-ques) [15]. PRO instruments can be
useful tools for evaluating health changes following
interventions if they are fit for purpose and accord with
international standards for rigorous development [16].
Patient-based outcome assessment in PUs is in its infancy;
few studies have assessed PROs and those that have done,
have mostly used generic instruments [14]. Using a
PU-specific PRO instrument in future research and
clinical practice could help improve the evidence-base
through research assessing effectiveness of PU therapies
from the patients’ perspective, facilitate clinician-patient
communication and shared decision making, prioritise
patient outcomes and preferences, and monitor changes
in outcomes during prevention, treatment, and post-
interventions [17, 18].
Comparative effectiveness research requires health-
care interventions to be evaluated not only in terms of
clinical outcomes, but a comprehensive evaluation
should incorporate patients’ perspectives of interven-
tions, both in terms of patients’ actual experiences (e.g.
symptoms and function), and their judgments about
the value of care (e.g. access to services) [16, 19]. The
original PU-QOL instrument was developed for use in
comparative effectiveness research with patients with
PUs receiving treatment interventions [15]. Given the
heterogeneity of the PU population, further work was
required to ensure that the PU-QOL instrument fit the
needs of all people with PUs including those with
superficial PUs, as well as patients at risk of PU devel-
opment [15]. To enable assessment of PROs in patients
at risk of PUs receiving preventative interventions, the
aim of this study was to modify the original PU-QOL
instrument so that it was suitable for use in compara-
tive effectiveness research with patients at high-risk of
PU development receiving preventative interventions.
Given that modifications were planned to the original
version, further aims were to undertake an evaluation
of the reliability and validity of the modified version,
and to also undertake responsiveness testing, which has
not previously been reported. Testing of psychometric
properties is an ongoing process of learning more about
the construct, making new predictions, and testing
them, particularly when modifications are made to a
previously tested PRO instrument – each supportive
study serves only to strengthen validity [20]. The
participants were acutely ill in-patients at high risk of
PU development receiving mattresses in common use
in healthcare settings and advocated in national and
international guidelines [1, 21] including ‘low tech’
constant low pressure specialist foam mattresses and
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‘high tech’ electrically powered mattresses which alternate
pressure distribution through air filled sacs.
Methods
Development of the PU-QOL-prevention instrument
The original PU-QOL is a self-report instrument [15],
comprising of three symptom (pain 8 items, exudate 8
items, odour 6 items) and seven function scales: four
physical functioning (sleep 6 items, movement and mo-
bility 9 items, daily activities 8 items, vitality 5 items);
two psychological well-being (emotional well-being 15
items, and self-consciousness and appearance 7 items);
and one social participation (9 items), plus a single item
for itchiness and a single item for global HRQOL. It is
intended for interview-administration [22] with patients
who have any category PU, and patients rate the amount
of “bother” attributed “during the past week” on a
3-point response scale (0 = not at all - 2 = a lot). Scale
scores are generated by summing items and then trans-
forming to a 0–100 scale. High scores indicate greater
patient bother. The PU-QOL instrument has been
validated for use with patients with PUs and is most ap-
propriate for people with severe PUs, as demonstrated
by a lack of items to represent people with little or no
bother due to PUs [15].
The original PU-QOL instrument was modified to
produce a prevention version (the PU-QOL-P instru-
ment). A group of 20 experts was convened including
specialist tissue viability nurses with a minimum of five
years experience managing people with PUs (recruited
from participating sites involved in PU-QOL evaluation
[23]), consumers with past experience of having PUs
(recruited via the Pressure Ulcer Research Service User
Network UK [24], and senior PRO methodologists with
expertise in developing and evaluating PRO instruments.
The expert group were asked to review the existing
PU-QOL instrument and complete a questionnaire that
asked about content (e.g. how relevant and representa-
tive are the issues to people at high-risk of pressure ulcer
development?); if any items were confusing, difficult to
understand or needed clarification; if any items were not
relevant to people at risk of PUs; and if any important
issues were missing.
Development of the PU-QOL-prevention instrument:
Results from expert group review
Feedback from the experts informed modifications to
the PU-QOL instrument. Specifically, we changed the
question stem from: “During the past week, how much
were you bothered by these feelings because of your
pressure sore(s)?” to “During the past week, how much
were you bothered by these feelings because of any pres-
sure area pain, soreness or discomfort, pressure sores or
treatments?”. Feedback about content that was missing
resulted in: four items added to the pain scale including
“feeling of altered sensation”; “dull ache”; “feeling sore”;
and “loss of feeling (e.g. numbness or paralysis)”; one
item added to the sleep scale (“being woken during
sleep”); and a single item developed for “overall
HRQOL” with response options: improved/got better,
the same or worsened. Two symptom scales (exudate
and odour) were considered only relevant for people
with PUs and therefore we introduced a skip question
(e.g. only complete if you have a PU). Two items were
removed from the Daily Activities scale: “doing shop-
ping” and “doing jobs around the house”. We also added
examples to one item “Doing things that you enjoy (e.g.
reading a book, watching a movie, talking on the
telephone, using a computer)”. We also added examples
to two items in the Malaise scale: “Feeling tired (e.g. in
need of sleep or rest)” and “Feeling fatigued (extreme
tiredness resulting from mental or physical exertion or
illness)”. We removed “because of your sore” from item
“Feeling like you have no control over your life because
of your sore” in the emotional wellbeing scale. The
participation scale was considered only relevant to
people who were not hospitalised so was excluded. No
changes were made to the Movement/mobility and
Appearance and self-consciousness scales or the single
item for itchiness.
Evaluation of the PU-QOL-prevention instrument
In order to assess the psychometric properties of the
PU-QOL-P instrument, we conducted a sub-analysis of
all patients recruited during August 2013 – November
2016 to the PRESSURE 2 trial that had completed both
the PU-QOL-P and SF12 instruments at baseline, and
provided responses to scale items. This initially included
all patients randomised to the trial but due to data bur-
den, only a sub-set of patients completed the PU-QOL-P
and SF12 instruments; patients were randomised to
either complete HRQOL instruments (i.e. PU-QOL-P
and SF12) or utility measures. A detailed description of
the methods for the PRESSURE 2 trial are published
elsewhere [25]. Briefly, PRESSURE 2 is a multicentre,
open-label, randomised, double triangular, group
sequential, parallel group trial conducted in acute
secondary care hospitals, community hospitals and
NHS-funded intermediate care/rehabilitation facilities in
England and Scotland. ‘High-risk’ patients admitted to
an in-patient facility with evidence of acute illness were
randomised, in a 1:1 allocation, to receive either a
high-specification foam mattress or alternating-pressure
mattress in conjunction with an electric profiling bed
frame. The primary objective of the trial was to compare
mattresses allocation in terms of the time to developing
a new Category 2 or above PU by 30 days post-treatment
phase. Secondary endpoints included time to developing
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a new Category 1 and 3 or above PUs, time to healing of
pre-existing Category 2 PUs, HRQOL, cost-effectiveness,
incidence of mattress change and safety.
PRO instruments
The PU-QOL-P instrument (described above) was
administered along with a generic measure of health
status, the SF12 [26]. The SF12 was chosen on the basis
of evidence from a systematic review of PRO instru-
ments for chronic wounds (including PUs) [14] and
practical issues relating to the patient population. Use of
the SF-36 was considered however it was decided by the
project team that it was too long for use with patients
with PUs (e.g. these patients are largely elderly, highly
dependent, and/or with high levels of co-morbidity
including acute and chronic illness). Instead, the SF-12,
a short version of the SF-36, was selected to reduce
respondent burden.
The SF-12 is a generic instrument that assesses health
status. It includes eight domains: physical functioning,
role-physical, body pain, general health, energy/fatigue,
social functioning, role-emotional and mental health. A
Physical Component Summary (PCS) and a Mental
Component Summary (MCS) score are generated. An
acute version of the SF12 is available that incorporates a
1-week recall period, which for this condition has been
found to be relevant [27]. The SF12 takes 2 min to
administer and has been validated for researcher-admin-
istration. Even though the SF12 has not specifically been
validated for use with people with PUs, it has
wide-spread use in other chronic wounds and dermato-
logical conditions to assess changes in health status
between groups; has been used with other chronic-skin
wound conditions to validate their corresponding
disease-specific PRO instruments; and has been vali-
dated for use with elderly people.
Statistical analyses
Descriptive analyses were conducted to describe demo-
graphic and clinical characteristics of the patient sample.
Standard psychometric analyses were used to evaluate
the PU-QOL-P. Analyses were performed using SPSS®
Statistics for Windows® version 22.0 (IBM, Armonk,
New York, USA). All analyses were conducted with
two-tailed tests at five level of significance. Analyses
were performed on a sub-sample of patients from the
PRESSURE 2 trial that completed both the PU-QOL-P
and SF12 questionnaires at baseline (n = 617; Fig. 1).
Responsiveness analysis was limited to patients who also
completed PU-QOL-Ps at 30 days post-treatment.
Scale-to-sample targeting and missing data
Scale-to-sample targeting was determined by investigat-
ing whether scale scores spanned the entire possible
scale range and floor/ceiling effects were low (less than
20%). Missing data rates were assessed by completeness
of item- and scale-level data. The minimum criterion for
computable scale scores was 50%.
Reliability
Internal consistency reliability was assessed for the eight
multi-item scales using Cronbach’s α coefficient, with an
α value of at least 0.8 regarded as adequate, and a value
of 0.7 or more as acceptable for group comparisons [28].
Within scale validity: Multitrait scaling
Multitrait scaling was used to evaluate the hypothesized
scale structure of the PU-QOL-P. Within-scale construct
validity assesses whether it is appropriate to sum
pre-specified groups of items to generate a scale score
that reflects a single underlying construct. Scaling as-
sumptions are satisfied with similar item means and
corrected item-total correlations (ITC) > 0.3. Corrected
ITCs > 0.3 indicate that items within each scale contain
a similar proportion of information. ITCs of 0.4–0.6
were considered moderate, and those exceeding 0.6 were
considered high [29].
Factor analysis
Exploratory factor analysis (EFA) was performed to
determine whether the proposed nine-scale structure of
the PU-QOL-P was supported in an at-risk population.
Exploratory factor analysis was chosen as the testing
population was very different to the population in which
Fig. 1 Flow of participants from the PRESSURE 2 trial included in the
psychometric sub-study
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the original PU-QOL instrument was tested in, and a
factor analysis had not previously been undertaken.
Direct Oblimin rotation methods allowed principal axis
factoring extraction deducing factor correlations. The
suitability of the data for EFA was assessed using the
Kaiser–Myer–Olkin measure of sampling adequacy (0.8)
and Bartlett’s test of sphericity (χ2 less than 0.01). EFA
contributes evidence towards construct validity.
Construct validity: Between scales validity
Convergent validity and discriminant validity were
assessed at the item level within the multitrait scaling
(e.g. convergent validity was confirmed when an item
correlated highly with the scale; ITC > 0.3), and at the
scale level using Spearman ρ rank-order correlation
coefficients between conceptually related scales of
PU-QOL-P and SF12. It was hypothesized that concep-
tually related scales would correlate more highly than
unrelated scales (high, r > 0.7; moderate, r 0.3–0.7; low,
r < 0.3). These criteria were used as guides to the magni-
tude of correlations, as opposed to pass–fail bench-
marks. As the PU-QOL-P assesses condition-specific
issues and the SF12 generic health issues, moderate
correlations were expected between the PU-QOL-P
scales for pain, mobility and movement, daily activities,
malaise, and emotional well-being with related scales of
the SF12.
Known-groups validity
Another aspect of construct validity, known-groups,
evaluated the extent to which PU-QOL-P scales differen-
tiate between groups of patients defined by clinical cri-
teria. We had difficulty devising clinical groups as the
literature proved little evidence towards clinical groups
known to differ. However, based on clinical experience,
we hypothesized that the PU-QOL-P scales, particularly
function scales, would differentiate between presence of
category 2 PU (no versus yes category 2 PU at baseline);
Braden score [30](completely limited versus no/slight
impairment); and adverse events [25] (AEs; no versus
yes AEs at 30 days post-treatment). As exploratory ana-
lyses, it was tentatively hypothesized that the PU-QOL-P
scales might differentiate between presence of category 1
PU (no versus yes category 1 PU at baseline) and PU
location (torso versus limb sites).
Each of the hypotheses was tested with an
independent-samples t-test, and a corresponding effect
size (ES) was calculated to indicate the size of the effect as
follows: small (0.20–0.49), moderate (0.50–0.79) or large
(0.80 or more) [31, 32].
Responsiveness-to-change analysis
Responsiveness can be considered longitudinal validity,
and analyses should be conducted in data where
clinically important change is expected. A sub-set of
patients with PUs at baseline that healed by 30 days
post-treatment, and patients with no PU at baseline that
developed one by 30 days post-treatment provided such
data. Paired sample t-test was used to evaluate the
significance of score changes between these two time
points, with expected significant changes in both symp-
tom and function scales in patients who have category 1
or 2 PUs at baseline but no PU at 30 days
post-treatment. Corresponding effect size values were
calculated as the mean change from baseline to 30 days
post-treatment, divided by the standard deviation of
change [31–33].
Results
Evaluation of the PU-QOL-prevention instrument
Baseline demographics
No notable differences were observed between the
analysis sample, who completed both PU-QOL-P and
SF12 instruments, and those excluded from the analysis
(i.e. those who only completed SF12) except that the
analysis sample included a few more people with
category 2 PUs. The analysis sample consisted of 617
patients (45.1% male), aged between 21.9 to 101.3 years
(mean 75.7), of which 141 (22.8%) had a category 1 or 2
PU and 61.4% reported presence of pressure-related pain
at baseline. The majority (99.8%) were Caucasian. More
than half (65.6%) were from secondary care hospital
setting with a medical condition (58.8%), and 70.7% were
considered as having very limited mobility according to
the Braden scale.
Scale-to-sample targeting and missing data
Scale scores spanned the entire scale ranges for all scales
apart from exudate (0–86) and odour (0–25) scales.
Global QOL mean score was near the scale midpoint,
however, all other mean scale scores were below 37, with
all scales exceeding the 20% criterion for floor effects.
Scale scores were computable for over 70% of respondents
(range 73.8–100%) (see Additional file 1).
Reliability
Internal consistency reliability was high with all scale
Cronbach coefficient alpha > 0.795 (range 0.795–0.970;
Table 1). During the analysis, items ‘putrid smell’ and
‘sickening smell’ were removed from the odour scale
because they had zero variance therefore the results are
based on a four not six item scale.
Factor analysis
We were unable to include the symptom scale items
into the factor analysis as there were fewer than two
people, at least one of the variables had zero variance,
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there was only one variable in the analysis, or correl-
ation coefficients could not be computed for all pairs of
variables. Conceptually, it made sense to consider the
items within our six function scales separately from the
symptom items.
The suitability of data for EFA was assessed. Kaiser–
Myer–Olkin value was 0.530; slightly below the recom-
mended value of 0.6 or above, but the Bartlett’s test of
sphericity reached statistical significance (χ2=10,159.415,
ρ 0.000). Inspection of the correlation matrix revealed
the presence of many correlation coefficients above 0.30
(all but one item), suggesting the EFA results could be
considered [34]. The EFA revealed the presence of five
components with eigenvalues exceeding 1, explaining
26.52, 4.24, 2.31, 1.63, and 1.36 of the variance respect-
ively. The five component solution explained a total of
73.59% of the variance.
The EFA (see Additional file 2) mostly supported a
six-function scale structure. Items with a factor-loading
coefficient ≥ 0.4 in each factor (scale) were considered
against our hypothesised scale structure. Factor one in-
cluded all items from the emotional wellbeing scale, apart
from one item “Feeling that people avoided you or treated
you differently now”, which loaded with items in the
appearance and self-consciousness scale, and the addition
of item “feeling helpless” from the appearance/self-
consciousness scale. All items from the appearance/
self-consciousness scale loaded together in factor five
except item “feeling helpless” and the addition of item
“Feeling that people avoided you or treated you differ-
ently now”.
Factor two included items from the movement and
daily activities scales. It is not surprising that movement
and daily activity items would group together into one
factor given that having reduced mobility would correl-
ate highly with reduced ability to participate in daily
activities; both scales assess aspects of physical function.
Item “Being emotionally close or affectionate with loved
ones (e.g. able to cuddle, being intimate)” from the
activity scale had weak item-factor weights (< 0.3) across
all factors. Inspection of missing item rates revealed
that the intimacy item was not answered by 12.2% of
the sample at baseline and by 25.5% of the sample at
30 days post-treatment. Factor three included all sleep
items. Factor four included all malaise items except
item “Feeling that your appetite has reduced”.
Within scale validity
Scaling assumptions were satisfied (Table 1). Mean
inter-item correlations for all scales ranged 0.355–
0.744. All item–own-scale correlations were moderate
to high (ITC; all > 0.45) for the six function scales but
not the three symptom scales. Corrected ITCs were
above 0.30 (range 0.337–0.803), satisfying recommended
criteria (> 0.3), except for the odour scale (corrected ITC
range 0.02–0.89).
Between scale validity
Correlations between PU-QOL-P and SF12 scales were
generally low to moderate (Table 2), suggesting that
PU-QOL-P scales provide distinct constructs (i.e.
disease-specific outcomes) from those measured by the
SF12. Convergent validity was confirmed by significant
correlations between hypothesized scales as expected. As
predicted, PU-QOL-P mobility scale correlated signifi-
cantly with SF12 physical function and role physical
scales. Also as expected the PU-QOL-P sleep scale,
correlated significantly with SF12 vitality scale, but unex-
pectedly the malaise scale did not. PU-QOL-P emotional
wellbeing and self-consciousness/appearance scales
correlated significantly with SF12 role emotional and
Table 1 PU-QOL-P scale level analyses - Reliability and scaling assumptions: Validity within-scale analysis








Pain (12) 617 0.864 0.355 0.128–0.713 0.364–0.642
Exudate (8) 60b 0.860 0.451 −0.024 – 0.865 0.337–0.824
Odour (6) 61b 0.795 0.492 −0.017 – 1.000 − 0.017 – 0.893
Sleep (7) 333 0.937 0.682 0.540–0.827 0.753–0.871
Movement & mobility (9) 177 0.963 0.744 0.593–0.928 0.803–0.909
Daily activities (6) 186 0.937 0.705 0.476–0.900 0.581–0.914
Malaise (5) 215 0.915 0.680 0.559–0.844 0.669–0.846
Emotional well-being (15) 220 0.970 0.681 0.447–0.900 0.630–0.869
Self-consciousness and appearance (7) 305 0.921 0.645 0.532–0.786 0.695–0.818
SEM standard error mean; IIC inter-item correlation; ITC item-total correlation (corrected for overlap)
aRange
bsample n = 62; only patients with a category ≥2 PU complete exudate and odour scale
cn estimated based on listwise deletion; observations that have one or more missing values across all variables are removed from analysis
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mental health scales. PU-QOL-P pain scale correlated
significantly with the SF12 pain scale (Table 2).
Known groups validity
Presence of category 2 PU (no versus yes category 2 PU at
baseline)
Known-group comparisons were not found to be
statistically significant for no versus yes category 2 PU
at baseline groups. However, small to moderate effect
size values were observed for all scales (see
Additional file 3). As expected, all scales apart from
the self-consciousness scale had higher mean scores in
the category 2 PU group compared to the no category
2 PU group. Mean differences in scores ranged from
1.28 to 9.52 (see Additional file 3). Higher scores indi-
cate worse symptom burden or impaired function.
Braden score (completely limited versus no/slight
impairment)
All mean scores were higher for the completely limited
group compared to the no/slightly impaired group in all
six PU-QOL-P function scales (see Additional file 3). As
expected, we found significant differences between com-
pletely impaired (M = 49.38, SD = 44.6) and no/slightly
impaired (M = 28.72, SD = 33.0) groups for the mobility
scale, p = 0.013 and the effect size was moderate (0.60);
and between completely impaired (M = 35.56, SD = 43.2)
and no/slightly impaired (M = 14.14, SD = 26.5) groups
for the daily activities scale, p = 0.007 and the effect size
was moderate (0.75).
Exploratory known groups included PU location (torso
versus limb sites)
Higher mean scores were observed in the three symptom
and the mobility scales in people with torso PUs compared
to those with limb PUs; effect sizes were small (see
Additional file 3). However, those with limb PUs reported
higher (or worse) mean scores in sleep, daily activities,
malaise, emotional wellbeing, and self-consciousness scales
compared to those who had torso PUs.
It is important to note that for all known groups we
had small samples (range 2–31 patients) therefore
known groups results are considered preliminary.
Responsiveness to change
In patients who had a category 1 or 2 PU at baseline that
healed by 30 days post-treatment, PU-QOL-P mean scale
scores from baseline to 30 days post-treatment were
statistically significant (P < 0.001) for scales pain (effect
size (ES) 0.86 large), sleep (ES 0.48 moderate), malaise (ES
0.61 moderate), emotional wellbeing (ES 0.65 moderate),
and appearance/self-consciousness (ES 0.60 moderate) but
not the two physical function scales (Table 3). In patients
who had a category 1 or 2 PU at baseline, all scales
showed higher mean scores at baseline compared to at 30
days post-treatment (range mean change 4.337–18.569).
In patients who did not have a category 1 or 2 PU at
baseline but developed one by 30 days post-treatment,
movement (ES 0.28 small), activities (ES 0.45 moder-
ate), malaise (ES 0.34 small), and self-consciousness
(ES 0.18 small) scale mean scores were higher at
baseline for people with no PU compared to those
who developed a PU by 30 days post-treatment; Table
4) but these results were not statistically significant.
This finding may in part be due to the fact that this
sample was acutely ill at baseline (e.g. immobile and
unwell), placing them at-risk of PUs and consequently
contributed to the PU developing. All other scale
scores were higher at 30 days post-treatment com-
pared to baseline, suggesting that pain, sleep and
emotional wellbeing is worse in patients with a PU
compared to those without, although again the differ-
ences were not statistically significant (Table 4). These
findings are preliminary due to the small sample sizes.
Table 2 Spearman’s rho correlations between PUQOL-R and SF12 scales (convergent validity)














Pain (12) 0.072 0.109a 0.320a 0.220a 0.168a 0.046 0.201a 0.261a
Exudate (8) 0.005 0.112 0.036 0.046 0.237 0.183 0.229 0.279b
Odour (6) 0.118 0.235 0.109 0.149 0.022 0.154 0.160 0.063
Sleep (7) 0.143a 0.137a 0.283a 0.203a 0.110b 0.008 0.246a 0.282a
Movement & mobility (9) 0.151a 0.133a 0.350a 0.214a 0.171a 0.036 0.299a 0.300a
Daily activities (6) 0.086 0.071 0.197a 0.139a 0.027 0.046 0.238a 0.218a
Malaise (5) 0.030 0.017 0.229a 0.205a 0.024 0.076 0.293a 0.274a
Emotional well-being (15) 0.034 0.037 0.227a 0.179a 0.012 0.030 0.323a 0.275a
Self-consciousness and appearance (7) 0.034 0.053 0.219a 0.119a 0.053 0.045 0.249a 0.206a
Itchiness (1) 0.006 0.080 0.130a 0.071 0.033 0.030 0.100b 0.100b
aCorrelation is significant at the 0.01 level (2-tailed)
bCorrelation is significant at the 0.05 level (2-tailed)
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Post-hoc analyses
The results from the psychometric analysis suggested
modifications that could be made to four of the
PU-QOL-P instruments’ scales. As such, we: (1) removed
item “appetite” from the malaise scale; (2) removed item
“intimacy” from the daily activities scale; (3) removed
item “helpless” from the self-consciousness scale and
added it to the emotional wellbeing scale; and (4) re-
moved item “people treat me differently” from the
emotional wellbeing scale and added it to the
self-consciousness scale. These changes were considered
to make sense conceptually, and re-analysis of the psy-
chometric properties supported these modifications.
Specifically, most patients were hospitalised at the time
of completing questionnaires so answering a question
about intimacy may have appeared irrelevant or consid-
ered too personal. Following the modifications, the
internal consistency reliability and within scale construct
validity was retained in all four scales, with the daily ac-
tivities, malaise, and emotional wellbeing scales values
for Cronbach alpha (range 0.914–0.971 for all four
modified scales), inter-item correlations (all > 0.502), and
corrected item-total correlations increasing (all > 0.681).
Although for the self-consciousness scale the Cronbach
alpha decreased marginally from 0.921 to 0.914, mean
inter-item correlations decreased from 0.645 to 0.628
(range from 05.32–0.786 to 0.502–0.795), and corrected
item-total correlations decreased from 0.695–0.818 to
0.681–0.812, all values remained within acceptable
ranges. Convergent validity results were strengthened
following the modifications. PU-QOL-P daily activity
scale was significantly correlated with SF12 physical
functioning and role physical scales, both PU-QOL-P
psychological scales were significantly correlated with
SF12 role emotional and mental health scales, and
PU-QOL-P malaise was now significantly correlated with
SF12 vitality scale (see Additional file 4).
Final PU-QOL-P
The final PU-QOL-P prevention version is a
researcher-administered instrument, comprising of three
symptom scales: pain (12 items), exudate (8 items),
odour (6 items); six function scales: four physical func-
tioning (sleep 7 items, movement and mobility 9 items,
daily activities 5 items, malaise 4 items) and two psycho-
logical wellbeing (emotional wellbeing 15 items and
self-consciousness and appearance 7 items); and three
single items for itchiness, appetite, and global QOL.
Table 4 PU-QOL-P Responsiveness over time: no PU at baseline (visit 0) compared to PU 30 days post-treatment end (visit 30)
Scales (n items) N Baseline scores Visit30 scores Mean change Effect Size CI P value
Mean (SD) Mean (SD)
Pain (12) 11 30.37 (27.522) 35.455 (34.676) −5.085 −0.16 −22.166, 12.000 0.522
Exudate (8) 0
Odour (6) 0
Sleep (7) 9 17.26 (23.487) 26.243 (30.829) −8.983 −0.33 −32.791, 14.828 0.410
Movement & mobility (9) 7 61.79 (48.055) 48.866 (44.792) 12.924 0.28 −3.955, 29.806 0.110
Daily activities (6) 7 9.64 (16.610) 3.5714 (9.449) 6.069 0.45 −4.596, 16.739 0.213
Malaise (5) 7 13.21 (24.440) 6.548 (12.697) 6.662 0.34 −8.416, 21.749 0.321
Emotional well-being (15) 11 11.31 (21.949) 18.375 (31.309) −7.065 −0.26 −24.106, 9.985 0.378
Self-consciousness and appearance (7) 11 4.24 (9.898) 2.597 (8.615) 1.643 0.18 −7.771, 11.061 0.705
Table 3 PU-QOL-P Responsiveness over time: PU at baseline (visit 0) compared to no PU 30 days post-treatment end (visit 30)
Scales (n items) N Baseline scores Visit30 scores Mean change Effect Size CI P value
Mean (SD) Mean (SD)
Pain (12) 31 27.57 (25.553) 9.001 (16.927) 18.569 0.86 9.637, 27.493 0.000
Exudate (8) 0
Odour (6) 0
Sleep (7) 29 27.82 (32.804) 14.03 (23.277) 13.790 0.48 1.655, 25.899 0.027
Movement & mobility (9) 21 37.86 (36.769) 21.17 (33.085) 16.688 0.48 −7.811, 41.179 0.171
Daily activities (6) 25 13.67 (28.956) 9.333 (24.244) 4.337 0.16 −10.069, 18.736 0.540
Malaise (5) 23 21.09 (37.049) 3.913 (13.731) 17.177 0.61 3.705, 30.642 0.015
Emotional well-being (15) 30 10.17 (20.837) 0.476 (2.608) 9.694 0.65 1.906, 17.475 0.016
Self-consciousness and appearance (7) 28 8.67 (19.668) 0.255 (1.350) 8.415 0.60 0.803, 16.034 0.032
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Patients rate the amount of “bother” attributed “During
the past week” on a 3-point response scale (e.g. 0 = not
at all - 2 = a lot). Scale scores are generated by summing
items and then transforming to a 0–100 scale. High
scores indicate greater patient bother. The PU-QOL-P
instrument is intended for interview-administration,
following a user manual, but could be self-completed by
patients depending on their preference [35]. It is suitable
for use with any adults at high risk of PU development
receiving preventative interventions in the acute and
community healthcare settings. Scales can be selected
depending on the nature of the research. For example,
the exudate and odour scales are not intended for people
at risk of PU development or with superficial category 1
PUs. Electronically defined ‘skip’ questions have been
added to assist in selecting scales relevant to each indi-
vidual’s circumstance or the exudate and odour scales
could be excluded in future prevention trials. It takes
around 15–20minutes to complete in its entirety.
Discussion
The PU field requires a strong evidence-base that
incorporates assessment of PROs. To fully capture and
quantify the patients’ perspective, appropriately con-
structed and validated PRO instruments are required.
PU-QOL-P scales mostly satisfy criteria for reliability,
validity, and responsiveness in line with recommended
FDA guidelines for PRO instruments [16]. The item-
total correlations, alpha coefficient and homogeneity
coefficient (inter-item correlation mean and range) pro-
vide evidence towards the reliability and internal
construct validity of the PU-QOL-P scales. The results
of the factor analysis mostly supported the use of the
items as hypothesised into six function scales. The weak
Kaiser–Myer–Olkin value questions suitability of the
data for factor analysis so of benefit would be further
confirmatory factor analysis in a new sample. However,
the second test to determine suitability of the data for
factor analysis, the Bartlet test, was supported, and the
factor structure emerged into conceptually meaningful
and logical factors. We also observed low correlations
between PU-QOL-P and SF12 scales hypothesised to be
conceptually related. We hypothesized that conceptually
related scales would correlate more highly than unre-
lated scales and used the standard correlation criteria as
guides to the magnitude of correlations, as opposed to
pass–fail benchmarks. Importantly, correlations for
scales hypothesised to be conceptually related were
consistently higher than for scales hypothesised to be
unrelated. Importantly, the two measures assess different
constructs so even though they might be theoretically
related, they are not the same (i.e. SF12 is not a criterion
measure of PU-specific HRQOL). Of clinical importance
is a PRO instruments’ ability to detect clinical groups
known to differ and to detect change when change has
occurred and these aspects were supported.
Some modifications were made to four scales, which
were supported by the post-hoc analyses, and the
changes made are considered conceptually sensible. For
example, items ‘putrid smell’ and ‘sickening smell’ were
removed from the odour scale because they assess smell
aspects associated with severe PUs. Item “Feeling that
your appetite has reduced” did not correlate with other
items hypothesised to make up the malaise scale. Upon
reflection, this item may be assessing a different
construct and could be retained as a single item for ap-
petite. As some changes were made to the scales, some
might argue that a further set of data should be collected
for further validation purposes. No one test confirms
validity, rather validation of a PRO instrument is an
ongoing process, with the accumulation of clinical valid-
ation data building a case for a particular instrument
functioning effectively in a particular population for a
specific purpose [36].
Our findings contribute evidence towards support that
people with category 2 PUs experience worse symptoms
and functioning outcomes than those without PUs.
People who are also physically limited experience worse
mobility outcomes and ability to participate in daily ac-
tivities than those who have no or only slight physical
impairment. PUs are often a secondary comorbidity and
a consequence of the primary condition a patient may
be experiencing. PUs contribute additional impairment
in physical function outcomes beyond those caused by
other comorbidities. Our exploratory hypothesis testing
suggests that patients with torso PUs experience worse
symptoms and more mobility problems, while patients
with limb PUs have more problems with sleep quality,
daily activities and malaise, lower emotional wellbeing,
and feel more self-consciousness.
Due to the small sample sizes in our hypothesised
known groups, we cannot make definitive conclusions.
However, we observed trends in scores in the right dir-
ection even though some were not statistically signifi-
cant. Small sample size affects the standard error so we
might expect to see large confidence intervals, however
sample size does not affect means, standard deviations
or effect size. Therefore, effect sizes are still relevant and
informative, even if non-significant correlations are
observed; which in this case may be attributed to sample
sizes being too small to detect significant differences.
Given that baseline data was completed in hospital
after admission for acute illness while the 30-day
post-treatment assessment was usually completed after
discharge, it is possible that the changed setting may have
contributed to improved HRQOL outcomes over time.
However, we did look at change in both directions for the
responsiveness analysis (i.e. no PU at baseline compared
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to PU at 30 days post treatment and also PU at baseline
but no PU at 30 days post treatment).
A limitation of our study was scale-to-sample target-
ing; mean scores were below scale mid-points and all
scales exceeded the 20% criterion for floor effects. How-
ever, given that we intended to recruit an at-risk popula-
tion (i.e. few people had category 1 or 2 PUs at baseline,
and none had category ≥3 PU), this finding is expected.
The floor effects indicate more homogeneity in the sam-
ple than is representative of the PU population. How-
ever, our study sample is representative of a high-risk
PU population, who may be experiencing pressure-area
related pain but that do not experience symptoms asso-
ciated with severe PUs such as exudate and odour, and
the PU-QOL-P version is intended for prevention trials.
The above limitations do not preclude use of the
PU-QOL-P instrument. PU-QOL-P scales can be in-
cluded as one outcome measure, amongst others, for
group comparisons in future PU research (e.g. clinical
trials). Work is underway to develop a short-form and to
test its clinical utility for use in clinical practice. As the
PU-QOL-P was developed and evaluated in the UK, the
validity and reliability are characteristics of the instru-
ment for a specific population (i.e. Caucasian English
speaking UK nationals). A language translation or
cross-cultural adaption may be required to ensure that
the PU-QOL-P is appropriate for cultures, languages
and ethnic groups outside the UK (see the PU-QOL-P
instrument website for guidance on language translation
and cross-cultural adaptation processes: https://med-
health.leeds.ac.uk/info/423/skin/1738/purpose_puqol/2.
Conclusions
This study makes important contributions to the PU
field. The PU-QOL-P instrument provides a means for
the comprehensive assessment of PU-specific PROs and
for quantifying the benefits and harms of PU preventa-
tive interventions from the patients perspective; thus far
lacking in the area. PRO assessment needs to become
more commonplace in the PU field so that the goal of
PU prevention and management can be to enhance and
maintain the HRQOL of people at risk of or with PUs.
The PU-QOL-P is a tool with which to evaluate whether
PU preventative interventions and the healthcare given
achieve this; outcomes that are ultimately best judged by
patients themselves.
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